Cel-Sci Corp (CVM)

$3.44 -0.22 (-6.01%)
Market Cap 30.36M
Revenue (ttm) 0.00
Net Income (ttm) -25.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,100
Avg Vol 56,774
Day's Range N/A - N/A
Shares Out 8.46M
Stochastic %K 0%
Beta 0.85
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
Isitreallyhim
Isitreallyhim Mar. 20 at 3:52 PM
$CVM @DrDizrespect amazing how these day traders always trumpet their amazing skills and selling/buying RIGHT before a big event and the money they made. Sort of like those gamblers at the the casinos that say they never lose. Why do you think those casinos are sooooo big ??? The funny part is they have their sorry ass posts you can look back on that prove their lies. Cheers !!
1 · Reply
DrDizrespect
DrDizrespect Mar. 20 at 2:46 PM
$CVM Cashed out of this failure at pretty close to the high years ago, we all saw the hype and played it like bosses. $35 right before the P3, (never had a chance), and rolled it into AVGO for my still long term hold. Sushi, pick one of your many accounts on here and post the 1,3,5, and all time charts of CVM and AVGO and talk to me about who’s on top. You’ve been taking the best down for years pal, and it’s so easy 😂
0 · Reply
Isitreallyhim
Isitreallyhim Mar. 20 at 12:33 PM
$CVM Dr Diz living in the past. It’s so funny how you guys still cry about 5 years ago. Get over it. New opportunity here.
1 · Reply
DrDizrespect
DrDizrespect Mar. 20 at 10:33 AM
$CVM hey look a multi- decade failure. Love that the same fools who have been pumping this with false claims are still here. You know the world has moved on right? We took every dime out of this when we hyped it up a few years ago, then dropped it off the building. Went public decades ago and hasn’t seen a dime since. Best you can do is load the rhetoric and try and guess the option play in this one. There is always a fool to buy the CVM “dream”. 😂
0 · Reply
Cruiser24
Cruiser24 Mar. 20 at 12:45 AM
$CVM BULLISH Friday would be nice. GOOD LUCK BULLS 7💎✋🤚💎💎✋🤚💎7 7 Another 1’s gone. Another 1’s gone. Another one bites the dust.
1 · Reply
ImmxBeliever
ImmxBeliever Mar. 19 at 8:09 PM
$CVM
1 · Reply
ImmxBeliever
ImmxBeliever Mar. 19 at 6:26 PM
$OBAI $CVM He’s so embarrassing @XL250 how’s cvm
0 · Reply
Isitreallyhim
Isitreallyhim Mar. 19 at 1:38 PM
$CVM @ThaDreadPirate agreed. Either they get the SFDA deal in the next two months or the company is toast....and we wait
1 · Reply
ThaDreadPirate
ThaDreadPirate Mar. 19 at 1:22 PM
$CVM only about 2.5 more months before they run out of cash. Maybe they can announce they are filing for approval in Iran to boost the stock price as they massively dilute their gullible bagholders.
1 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 6:01 PM
$CVM ALERT – FDA PIVOTAL TRIAL - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820513
2 · Reply
Latest News on CVM
CEL-SCI Reports Fiscal First Quarter 2026 Results

Feb 18, 2026, 9:00 AM EST - 4 weeks ago

CEL-SCI Reports Fiscal First Quarter 2026 Results

CEL-SCI Reports Fiscal 2025 Results

Dec 29, 2025, 9:00 AM EST - 2 months ago

CEL-SCI Reports Fiscal 2025 Results

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 20, 2025, 9:00 AM EDT - 5 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Oct 10, 2025, 8:00 AM EDT - 5 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 7 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 7 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 7 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 7 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Aug 13, 2025, 9:15 AM EDT - 7 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 8 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 9 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 9 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 9 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 10 months ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 10 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 10 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 10 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 11 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 11 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 1 year ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 2 years ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Isitreallyhim
Isitreallyhim Mar. 20 at 3:52 PM
$CVM @DrDizrespect amazing how these day traders always trumpet their amazing skills and selling/buying RIGHT before a big event and the money they made. Sort of like those gamblers at the the casinos that say they never lose. Why do you think those casinos are sooooo big ??? The funny part is they have their sorry ass posts you can look back on that prove their lies. Cheers !!
1 · Reply
DrDizrespect
DrDizrespect Mar. 20 at 2:46 PM
$CVM Cashed out of this failure at pretty close to the high years ago, we all saw the hype and played it like bosses. $35 right before the P3, (never had a chance), and rolled it into AVGO for my still long term hold. Sushi, pick one of your many accounts on here and post the 1,3,5, and all time charts of CVM and AVGO and talk to me about who’s on top. You’ve been taking the best down for years pal, and it’s so easy 😂
0 · Reply
Isitreallyhim
Isitreallyhim Mar. 20 at 12:33 PM
$CVM Dr Diz living in the past. It’s so funny how you guys still cry about 5 years ago. Get over it. New opportunity here.
1 · Reply
DrDizrespect
DrDizrespect Mar. 20 at 10:33 AM
$CVM hey look a multi- decade failure. Love that the same fools who have been pumping this with false claims are still here. You know the world has moved on right? We took every dime out of this when we hyped it up a few years ago, then dropped it off the building. Went public decades ago and hasn’t seen a dime since. Best you can do is load the rhetoric and try and guess the option play in this one. There is always a fool to buy the CVM “dream”. 😂
0 · Reply
Cruiser24
Cruiser24 Mar. 20 at 12:45 AM
$CVM BULLISH Friday would be nice. GOOD LUCK BULLS 7💎✋🤚💎💎✋🤚💎7 7 Another 1’s gone. Another 1’s gone. Another one bites the dust.
1 · Reply
ImmxBeliever
ImmxBeliever Mar. 19 at 8:09 PM
$CVM
1 · Reply
ImmxBeliever
ImmxBeliever Mar. 19 at 6:26 PM
$OBAI $CVM He’s so embarrassing @XL250 how’s cvm
0 · Reply
Isitreallyhim
Isitreallyhim Mar. 19 at 1:38 PM
$CVM @ThaDreadPirate agreed. Either they get the SFDA deal in the next two months or the company is toast....and we wait
1 · Reply
ThaDreadPirate
ThaDreadPirate Mar. 19 at 1:22 PM
$CVM only about 2.5 more months before they run out of cash. Maybe they can announce they are filing for approval in Iran to boost the stock price as they massively dilute their gullible bagholders.
1 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 6:01 PM
$CVM ALERT – FDA PIVOTAL TRIAL - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820513
2 · Reply
Isitreallyhim
Isitreallyhim Mar. 18 at 3:43 PM
$CVM who is this guy @BioGLovesMe on this board. In reading this he does realize that the CEO confirmed that questions were answered at the end of December per a request from the SFDA and they have 60 business days to respond. That should put us around March 31st for a response. It seems to me holding until then is the smart choice. Again I'm new here so let me know your thoughts.
2 · Reply
BioGLovesMe
BioGLovesMe Mar. 18 at 2:50 PM
$CVM How many working days has it been now since August 13th? SFDA says BMD designation requests take 30 working days to process. What is the delay? Why no communications from SFDA, Dallah or First Berlin? These are simple questions you lemmings should be asking. Also take a look at their cash holdings and burn rate. Dilution can happen at any time and put you firmly in the Permabaggie Asylum.
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 2:26 PM
MOMO'S BREAKOUT BOARD : $CVM ALERT – FDA PIVOTAL TRIAL LOADING S... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177408573 via @Investors_Hub
1 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 1:07 PM
🚨 $CVM ALERT – FDA PIVOTAL TRIAL LOADING SUMMER 2026! 🔥🩺💥 https://youtube.com/shorts/UAGkEQ6mhz4 #CVM #STOCKSTOWATCH #TheBullRunShow #STOCKS @TheBullRunShow @DAVANZO
1 · Reply
Isitreallyhim
Isitreallyhim Mar. 18 at 12:15 PM
$CVM new here. Who is this Sushi guy? Seems like he needs some serious help.
2 · Reply
ImmxBeliever
ImmxBeliever Mar. 17 at 6:20 PM
$NWBO $CVM Biggest clown He will lose it all Laughing
2 · Reply
CashNCarry
CashNCarry Mar. 17 at 4:53 PM
$CVM Boom!!
2 · Reply
Cruiser24
Cruiser24 Mar. 17 at 4:19 PM
$CVM BULLISH What you cackling about Bio? GOOD LUCK BULLS 🍀💎✋🤚💎💎✋🤚💎🍀 One day closer. Have you laid that egg today. I hope so. That’s all your worth.
1 · Reply
Isitreallyhim
Isitreallyhim Mar. 17 at 2:45 PM
$CVM approval coming soon. Get some !!!
1 · Reply
BioGLovesMe
BioGLovesMe Mar. 17 at 2:32 PM
$CVM Cmon lemmings, get excited!
1 · Reply
BooBoo1868
BooBoo1868 Mar. 17 at 11:22 AM
$CVM News was released 216 days ago... Geert said a 60 day turn around... just saying
1 · Reply
RealMcCoy
RealMcCoy Mar. 17 at 7:42 AM
$CVM I am new here, is this a good POS
2 · Reply